Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Amgen Stop The Bleeding As FDA Presses For A Low-Dose Aranesp Trial?

This article was originally published in The Pink Sheet Daily

Executive Summary

CardioRenal Advisory Committee will discuss whether there should be a trial testing lower dosing limits in CKD patients. With sales declines a forgone conclusion regardless, Amgen hopes to avoid the expense of a complex study.

You may also be interested in...



Aranesp Gets Advisory Committee Boost As Amgen Braces For Labeling Negotiations

FDA panel votes against reducing of darbepoietin alfa in patients with failing kidneys who are headed toward dialysis.

Aranesp Gets Advisory Committee Boost As Amgen Braces For Labeling Negotiations

FDA panel votes against reducing of darbepoietin alfa in patients with failing kidneys who are headed toward dialysis.

FDA Advisory Committee Will Review ESAs In The Renal Setting Oct. 18

Meeting also could be next step in the process of determining whether safety issues are enough to drive changes to erythropoiesis-stimulating agent reimbursement at CMS.

Related Content

Topics

UsernamePublicRestriction

Register

PS071305

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel